SOTAC PHARMACEUTICALS LIMITED (SOTAC): Financials & Fundamentals History

Share price

Closing priceAdjusted for splits and bonus issues.

3M1Y3YAll

₹130 latest close · +20.3% over the last 90 sessions

₹130 month-end · +0.1% over 12 months

₹130 month-end · +13.0% over 3 years

₹130 month-end · +13.0% since Apr '23

52-week range ₹86.00 to ₹202.80 · 1-year volatility 61.0%

Was the rally earned?

1 year3 years

-6%share price, 1 yearEarnings-driven

Mostly earnings.

Per-share earnings took off 32 points, while the multiple moved less (P/E 19.1x to 24.9x).
The share count fell 7%.

Net profit growth-39 ptsNet profit fell about 33%, which lowers the price.

P/E change+26 ptsThe P/E rose from 19.1x to 24.9x, which lifts the price.

Share count change+7 ptsShare count fell 7%, which lifts the price.

+4%share price, 3 yearsRoughly flat

The share price was roughly flat over 3 years (+4%).
The share count rose 38%.

Net profit growth+71 ptsNet profit rose about 100%, which lifts the price.

P/E change-34 ptsThe P/E fell from 34.9x to 24.9x, which lowers the price.

Share count change-32 ptsShare count rose 38%, which lowers the price.

What do "pts" mean?

"pts" are percentage points of the share price return. The parts add up to the total shown for each period. Because price = P/E × net profit ÷ share count, higher profit pushes the price up, a higher P/E pushes it up, and more shares push it down.

Example: if the price rose 34% and profit growth accounts for +58 pts while a lower P/E accounts for -24 pts, then 58 - 24 = 34. The +58 is not the profit growth rate itself: it is the part of the price move that profit growth explains.

Not shown for 5 years: earnings were negative at one end, or there is not enough history.

Net profit is trailing twelve months as reported with a 60-day lag.

Compare this with SUN PHARMACEUTICAL INDUSTRIES

How rough has the ride been?

Maximum drawdown-53.8%not yet recovered

1-year volatility61.0%annualised

Drawdown from peak

Largest drawdowns

-53.8% (2024-07 peak to 2026-08 low, not yet recovered)

-33.5% (2024-03 peak to 2024-06 low, recovered 2024-07)

-20.7% (2023-05 peak to 2023-12 low, recovered 2024-02)

Is it expensive against its own past and its peers?

24.9xP/E todayWithin its usual range

Against its own history41st percentile

CheapestMedian 29.7xDearest

Usual range 16.1x to 35.1x since 2023-04.

Against Health Technology24.9x vs 37.0x

This company

24.9x

Sector median

37.0x

33% below the Health Technology median.

P/EP/BP/S

P/E (this company)10th to 90th percentile of its own historyIts medianHealth Technology median

The chart loads when you open this tab.

P/B (this company)10th to 90th percentile of its own historyIts medianHealth Technology median

The chart loads when you open this tab.

P/S (this company)10th to 90th percentile of its own historyIts medianHealth Technology median

How to read this

Shaded band: 10th to 90th percentile of the company's own P/E history; dotted line: its median; orange line: sector median (companies with a positive multiple, at least 5 in the sector).

Sector figures are built from today's listed companies, so they exclude companies that are no longer listed.

All terms explained in the glossary →

How Health Technology is valued

Where does it rank among Health Technology peers?

Each cell is the company's percentile rank among its Health Technology peers (non-financial companies) that month.
Darker is better-ranked.
Rows marked ↓ are inverted (lower debt, shorter cash cycle and a lower P/E rank higher).

Where it ranks today

ROCE40th▼ 10 pts vs a year ago
Revenue growth25th▲ 8 pts vs a year ago
EPS growth22nd▼ 68 pts vs a year ago
Debt/equity ↓14th▲ 7 pts vs a year ago
Cash cycle ↓63rd▲ 9 pts vs a year ago
P/E ↓70th▼ 12 pts vs a year ago
12M momentum41st▼ 48 pts vs a year ago

Rank history

ROCE

Revenue growth

EPS growth

Debt/equity ↓

Cash cycle ↓

P/E ↓

12M momentum

Dec '21Jul '22Jan '23Jul '23Jan '24Jul '24Jan '25Jul '25Jan '26Jul '26Nov '26

Lower rank Higher rank Not enough data

Percentiles use today's listed companies in the sector and need at least 5 peers with a value; grey cells have too few.
ROE is computed from net profit and book value where the source does not report it.

The Health Technology sector page Watch it move against Health Technology in the Observatory

What is the price implying?

~23%annual earnings growth implied by the price

At a P/E of 39.3x, the price would imply about 23.3%/yr earnings growth for 10 years under the same assumptions, but it is not ranked.

Below the ₹1,000 cr market-cap floor used for the lists.

“Implied growth” is what the current price would require under our stated assumptions, not what we expect.

What prices imply across Health Technology The market-wide Expectations lists

Key figures

Share Priceclose 9 Nov: ₹130.00
P/E: 24.9x
ROCE: 12.0%
Market Cap: ₹143 cr
Revenue (TTM): ₹101 cr
P/S: 1.4x
P/B: 2.4x
ROE: 9.7%
Debt / Equity: 0.6x
Promoter Holding: 72.8%
12M Momentum: 0.1%

52-week range

₹86.00₹202.80

38% of the way from its 52-week low to its high

Price risk

1Y volatility

61.0%

Beta vs sector

1-year daily

0.61

Balance sheet & cash

Interest cover

operating profit ÷ interest

3.3x

Cash from profit, 3Y

operating cash flow ÷ net profit

-0.16x

low

Share count, 1Y

unchanged

Are profits backed by cash?

3 of 6checks within range2 beyond a threshold

Other income reliance0%Within range

Other income as a share of pre-tax profit (trailing twelve months): 0.0%. Bands: below 15%, 15% to 35%, above 35%.

Tax rate—Not enough data

Not enough reported data to compute this.

Cash conversion-0.16xBeyond threshold

Operating cash flow divided by net profit over the last three fiscal years: -0.16x (cash from operations ₹-3 cr, net profit ₹19 cr). Bands: 0.8x and above, 0.5x to 0.8x, below 0.5x.

Free cash flow1 of 5 yrsBeyond threshold

Fiscal years with positive free cash flow in the last 5: 1. Bands: at least 80% of years, 40% to 80%, below 40%.

Receivable days vs history+27 daysNear threshold

Debtor days are above the median of the previous three fiscal years by 27 days (119 vs 92). Bands: under 15 days, 15 to 45, over 45.

Capital work in progress4% of fixed assetsWithin range

Capital work-in-progress is 4% of fixed assets. Bands: not rising or up to 30%; rising for three years and above 30%; rising and above 60%.

Payable days+22 days / 2 yrsWithin range

Days payable changed by +22 over two years. Bands: rise of up to 30 days; more than 30 days.

Tap a check to see how it is measured

How to read this

Each check is a named rule with fixed thresholds, not a score. Annual statements are the latest restated figures, so a past year may differ from what was originally reported.

All terms explained in the glossary →

Who has been buying and selling?

Over 3 years, FIIs added 3.9 pts.
The number of shareholders fell from 784 to 221 (-72%) between Jun 2023 and Mar 2026.

Holdings, Mar '26

How each group changed

GroupJun '23Mar '26Change

Promoters72.8%72.8%0.0 pts

FIIs12.9%16.8%+3.9 pts

DIIs0.0%0.0%0.0 pts

Public and others14.3%10.4%-3.9 pts

Number of shareholders

221shareholders-72% since Jun '23

Quarterly shareholding as reported, labelled by the quarter it covers (it becomes visible about two months later).
Shareholder counts are only available for recent quarters.

This quarter's smart-money board

What happened next to similar setups

−2.9%typical 12-month return vs the marketNot meaningfully different from the base rate

We found 50 past situations where a non-financial company looked like SOTAC PHARMACEUTICALS LIMITED today on valuation, return on capital, debt, growth, price momentum, size and volatility.
Over the following 12 months the middle half of them returned −30% to +24% vs the market, against 0% for all non-financial companies in the same months.
The gap against the base rate (−2.6%, 80% range −13.4% to +1.0%) is within what chance and overlapping periods produce.

Where the 50 outcomes landed

Each dot is one past situation (hover or tap for details) · Solid dots are the closest matches, listed below · Shaded is the middle half of all companies in the same months · 3 beyond the range shown, drawn at the edge

Similar setups' median

−2.9%

All companies' median

−0.3%

Beat the market

44% vs 50%

50 past situations · 50 companies · 37 months · 2020–2025

The closest matches

Company	When	P/E	ROCE	12M mom.	Drawdown	Next 12 months
SHIVATEX Process Industries	Apr 2020	12x	—	−33%	−55%	+21%
RPPL Process Industries	Oct 2022	23x	—	+28%	−30%	+2%
SOMICONVEY Producer Manufacturing	Aug 2025	30x	10%	−22%	−36%	−40%
HPIL Process Industries	Sep 2023	39x	9%	+31%	−15%	−14%
TPLPLASTEH Process Industries	Jun 2022	26x	14%	+10%	−38%	+26%

Show the other 3 matches

Company	When	P/E	ROCE	12M mom.	Drawdown	Next 12 months
UNIVASTU Industrial Services	May 2023	20x	17%	+24%	−18%	+52%
SURANASOL Electronic Technology	Feb 2020	13x	—	−10%	−43%	−5%
ARHAM Consumer Durables	Nov 2024	46x	—	+38%	−26%	+13%

How reliable is this?

Matched on P/E, P/S, ROCE, debt/equity, interest cover, revenue growth, 12-month momentum, drawdown from 12-month high, size and volatility. Closest on: interest cover, 12-month momentum and ROCE. Not used (unavailable for this company): operating margin. One match per company and at most 7 from any one month.

Independent periods: the matches fall in 6 distinct 12-month windows. Matches from nearby months share the same market conditions, so fewer windows means less evidence.

How this is built

This is history, not a forecast. These are past situations where other companies had broadly similar reported numbers and price trends. What happened to them does not tell you what will happen to SOTAC PHARMACEUTICALS LIMITED. The comparison covers only 2020–2025, a single market period, and only companies still listed today. Companies that were delisted or went bankrupt are missing, which makes past outcomes look better than they were. Returns exclude dividends and are measured against an ApnaFunda-built index, not an official benchmark. Fundamentals are matched on a 60-day assumed reporting lag, not actual announcement dates. Its historical skill has not yet been measured. Past patterns may not repeat.

Methodology

How historical analogs are built

Data as of 2026-11-09. Outcome pool: Jan 2020 to Oct 2025.

For every company we look at the situation it is in today (valuation, return on capital, margins, debt, growth, 12-month price momentum, drawdown, size and volatility) and find past company-months that looked most like it. We then show what happened to those past situations over the following 12 months, measured against the ApnaFunda All index and against the base rate. It describes history. It does not predict anything.

What is compared

Feature	Weight	Non-financial	Financial
P/E	1	yes	yes
P/S	1	yes	—
P/B	1	—	yes
ROCE	1	yes	—
operating margin	1	yes	—
ROE	1	—	yes
debt/equity	0.75	yes	—
interest cover	0.5	yes	—
revenue growth	0.75	yes	yes
12-month momentum	1	yes	yes
drawdown from 12-month high	0.75	yes	yes
size	0.75	yes	yes
volatility	0.5	yes	yes

Weights were set by judgement before any outcome was looked at and are never tuned on results. Loss-making companies (negative P/E or net profit) are only matched with other loss-making companies. Banks, NBFCs and insurers are compared only with each other and use a different feature set. Every feature is converted, month by month, to its rank among companies in the same pool in that month, so a P/E of 30 in a hot market and a P/E of 22 in a cold one can match if both were equally expensive for their time. Only that month's data is used.

How closeness and the sample are defined

Distance is the weighted root-mean-square gap between the standardised features both companies have. A match needs at least 70% of the query's feature weight, a distance of at most 0.9, and 30 matches at minimum to be shown. We keep up to 50 matches with these exclusions: never the company itself, one match per company (its closest month), and at most 7 from any one calendar month so a single market episode cannot dominate.

Base rate

The base rate is the distribution of 12-month returns, relative to the market, of every eligible company-month in the same pool, with each month weighted to match the months the analogs came from. It answers: how did a random company do in these same months? Because matches from nearby months share the same market conditions, we also report the number of distinct 12-month windows behind a result, and a bootstrap that resamples months decides whether the analog median differs from the base rate at all. "Not meaningfully different" is the usual outcome and the page copy is written for it.

Limits you should know

One market period. The outcome pool covers 2020–2025 only (70 months), including the 2020 crash and the 2020–21 rally.
Survivorship. Only companies listed today are included. Delisted and bankrupt companies are missing, which flatters past outcomes, particularly for distressed-looking setups.
Price return only. Dividends are excluded, and the benchmark is an ApnaFunda market-cap-weighted index of the same listed companies, not an official index.
Reporting lag. Fundamentals are matched on an assumed 60-day lag after the quarter end, not on real announcement dates.
Pools: non-financial: 98,395 company-months from 2019 companies; financial: 5,659 company-months from 108 companies. 2349 companies currently have a result; the rest are suppressed because too few comparable situations exist.

Does it work? A walk-forward check

The walk-forward check has not been run for this build, so skill is shown as not yet measured.

Disclaimer

This is history, not a forecast. These are past situations where other companies had broadly similar reported numbers and price trends. What happened to them does not tell you what will happen to any company shown. The comparison covers only 2020–2025, a single market period, and only companies still listed today. Companies that were delisted or went bankrupt are missing, which makes past outcomes look better than they were. Returns exclude dividends and are measured against an ApnaFunda-built index, not an official benchmark. Fundamentals are matched on a 60-day assumed reporting lag, not actual announcement dates. Its historical skill has not yet been measured. Past patterns may not repeat.

What changed?

20 events since Jun '23

2026
OctPeer rankSlipped to the bottom quartile of Health Technology on EPS growth (from the 3rd quartile).
AugPriceFell 54% from the Jul 2024 peak to the Aug 2026 low.
JunResultsYear-on-year EPS growth turned negative.
JunPeer rankSlipped to the 3rd quartile of Health Technology on EPS growth (from the top quartile).
JunDividendStarted paying a dividend (payout 4% of profit).
AprPeer rankSlipped to the 3rd quartile of Health Technology on ROCE (from the 2nd quartile).
2025
DecValuationP/E fell below the 10th percentile of its own history to date (16.9x).
JunInstitutionsFII + DII holding rose 6.9 pts over 1 quarter to 15.8%.

Show 12 earlier events

2025
JunValuationP/E fell below the 10th percentile of its own history to date (20.0x).
JunPeer rankMoved into the 2nd quartile of Health Technology on ROCE (from the 3rd quartile).
2024
NovDebtDebt / equity halved over 12 months to 0.56x.
JulPriceRegained the 2024-03 peak, 1 month after the low.
JunResultsRevenue (TTM) reached a new high of ₹104 cr.
JunPriceFell 34% from the Mar 2024 peak to the Jun 2024 low.
JunPeer rankMoved into the 3rd quartile of Health Technology on ROCE (from the bottom quartile).
JunDebtDebt / equity fell below 1.0x (0.56x).
JunSharesShare count is up 37.5% over 12 months.
AprDebtDebt / equity halved over 12 months to 1.16x.
2023
DecInstitutionsFII + DII holding fell 4.4 pts over 1 quarter to 8.5%.
JunResultsEPS (TTM) turned positive.

Events are generated from the data by fixed rules.
The month shown is when the change became visible in the reported figures, assuming a 60-day lag after each quarter end; it is not an announcement date.

Where price and fundamentals disagree, market-wide Rewind the whole market to any month

Monthly history44 months · 2023-04 to 2026-11

Month	P/E	Revenue (TTM)	ROE	ROCE	Debt / Equity
2026-11	24.9x	₹101 cr	9.7%	12.0%	0.6x
2026-10	21.4x	₹101 cr	9.7%	12.0%	0.6x
2026-09	—	—	—	—	—
2026-08	17.3x	₹101 cr	9.7%	12.0%	0.6x
2026-07	17.6x	₹101 cr	9.7%	12.0%	0.6x
2026-06	20.1x	₹101 cr	9.7%	12.0%	0.6x
2026-05	15.3x	₹100 cr	16.2%	15.0%	0.8x
2026-04	16.1x	₹100 cr	16.2%	15.0%	0.8x
2026-03	15.0x	₹100 cr	16.2%	15.0%	0.8x
2026-02	15.3x	₹100 cr	16.2%	15.0%	0.8x
2026-01	16.3x	₹100 cr	16.2%	15.0%	0.8x
2025-12	16.9x	₹100 cr	16.2%	15.0%	0.8x
2025-11	19.1x	₹100 cr	16.2%	15.0%	0.8x
2025-10	17.9x	₹100 cr	16.2%	15.0%	0.8x
2025-09	14.9x	₹100 cr	16.2%	15.0%	0.8x
2025-08	18.9x	₹100 cr	16.2%	15.0%	0.8x
2025-07	17.2x	₹100 cr	16.2%	15.0%	0.8x
2025-06	20.0x	₹100 cr	16.2%	15.0%	0.8x
2025-05	32.5x	₹104 cr	9.4%	10.0%	0.6x
2025-04	32.3x	₹104 cr	9.4%	10.0%	0.6x
2025-03	30.7x	₹104 cr	9.4%	10.0%	0.6x
2025-02	26.6x	₹104 cr	9.4%	10.0%	0.6x
2025-01	27.6x	₹104 cr	9.4%	10.0%	0.6x
2024-12	28.2x	₹104 cr	9.4%	10.0%	0.6x
2024-11	29.7x	₹104 cr	9.4%	10.0%	0.6x
2024-10	32.3x	₹104 cr	9.4%	10.0%	0.6x
2024-09	34.1x	₹104 cr	9.4%	10.0%	0.6x
2024-08	40.1x	₹104 cr	9.4%	10.0%	0.6x
2024-07	38.4x	₹104 cr	9.4%	10.0%	0.6x
2024-06	36.0x	₹104 cr	9.4%	10.0%	0.6x
2024-05	32.1x	₹77 cr	15.0%	—	1.2x
2024-04	34.4x	₹77 cr	15.0%	—	1.2x
2024-03	33.8x	₹77 cr	15.0%	—	1.2x
2024-02	43.3x	₹77 cr	15.0%	—	1.2x
2024-01	35.1x	₹77 cr	15.0%	—	1.2x
2023-12	33.0x	₹77 cr	15.0%	—	1.2x
2023-11	34.9x	₹77 cr	15.0%	—	1.2x
2023-10	32.1x	₹77 cr	15.0%	—	1.2x
2023-09	34.6x	₹77 cr	15.0%	—	1.2x
2023-08	35.1x	₹77 cr	15.0%	—	1.2x
2023-07	32.8x	₹77 cr	15.0%	—	1.2x
2023-06	34.1x	₹77 cr	15.0%	—	1.2x
2023-05	—	₹49 cr	-29.3%	-5.0%	8.5x
2023-04	—	₹49 cr	-29.3%	-5.0%	8.5x

Methodology and data notes